Drug intelligence / Profile preview

sorfequiline

Development stage: Phase 2
Lead developer: TB Alliance
Modality: Small Molecules
Administration: Oral

Overview

Sorfequiline (GSK3657322) is a novel small molecule antimalarial agent currently under development for the treatment of malaria. It functions by inhibiting **Plasmodium falciparum ATPase 4 (PfATP4)**, a P-type sodium-transporting ATPase located on the parasite's plasma membrane. By blocking this pump, sorfequiline disrupts sodium homeostasis within the parasite, leading to a lethal rise in intracellular sodium levels and rapid parasite clearance. Developed by GSK in collaboration with organizations like the Medicines for Malaria Venture (MMV), it is designed as a fast-acting component of next-generation combination therapies to address drug-resistant strains of *Plasmodium falciparum*.

Other names: sorfequiline

Targets

PfATP4 (Plasmodium falciparum ATPase 4)

Beyond the preview

Go deeper on sorfequiline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sorfequiline.

Explore the full profile